Clonal Proliferation Within Smooth Muscle Cells in Unstable Human Atherosclerotic Lesions

Abstract

BACKGROUND: Studies in humans and mice using the expression of an X-linked gene or lineage tracing, respectively, have suggested that clones of smooth muscle cells (SMCs) exist in human atherosclerotic lesions but are limited by either spatial resolution or translatability of the model. METHODS: Phenotypic clonality can be detected by X-chromosome inactivation patterns. We investigated whether clones of SMCs exist in unstable human atheroma using RNA in situ hybridization (BaseScope) to identify a naturally occurring 24-nucleotide deletion in the 3′UTR of the X-linked BGN (biglycan) gene, a proteoglycan highly expressed by SMCs. BGN-specific BaseScope probes were designed to target the wild-type or deletion mRNA. Three different coronary artery plaque types (erosion, rupture, and adaptive intimal thickening) were selected from heterozygous females for the deletion BGN. Hybridization of target RNA-specific probes was used to visualize the spatial distribution of mutants. A clonality index was calculated from the percentage of each probe in each region of interest. Spatial transcriptomics were used to identify differentially expressed transcripts within clonal and nonclonal regions. RESULTS: Less than one-half of regions of interest in the intimal plaque were considered clonal with the mean percent regions of interest with clonality higher in the intimal plaque than in the media. This was consistent for all plaque types. The relationship of the dominant clone in the intimal plaque and media showed significant concordance. In comparison with the nonclonal lesions, the regions with SMC clonality had lower expression of genes encoding cell growth suppressors such as CD74, SERF-2 (small EDRK-rich factor 2), CTSB (cathepsin B), and HLA-DPA1, among others. CONCLUSIONS: Our novel approach to examine clonality suggests atherosclerosis is primarily a disease of polyclonally and to a lesser extent clonally expanded SMCs and may have implications for the development of antiatherosclerotic therapies.

Enhanced vasorin signaling mitigates adverse cardiovascular remodeling

“…Increased proliferation of VSMCs is associated with various vascular remodeling processes and diseases, including age‐associated intimal thickening, atherosclerosis, and in‐stent restenosis. 5 , 27 , 35 , 36 , 37 , 38 One main factor contributing to phenotype switch of VSMCs from quiescent to proliferative is the activation of inflammatory signaling cascades, which lead to the downregulation of crucial contractile structural and cytoskeletal proteins. 4 , 5 , 23 , 27 In this context, the smooth muscle cell‐specific protein VASN is emerging as a novel regulator of VSMC proliferation and differentiation both in vitro and in vivo.…”